The long and short non-coding RNAs modulating EZH2 signaling in cancer. 2022

Sepideh Mirzaei, and Mohammad Hossein Gholami, and Kiavash Hushmandi, and Farid Hashemi, and Amirhossein Zabolian, and Israel Canadas, and Ali Zarrabi, and Noushin Nabavi, and Amir Reza Aref, and Francesco Crea, and Yuzhuo Wang, and Milad Ashrafizadeh, and Alan Prem Kumar
Department of Biology, Faculty of Science, Islamic Azad University, Science and Research Branch, Tehran, Iran.

Non-coding RNAs (ncRNAs) are a large family of RNA molecules with no capability in encoding proteins. However, they participate in developmental and biological processes and their abnormal expression affects cancer progression. These RNA molecules can function as upstream mediators of different signaling pathways and enhancer of zeste homolog 2 (EZH2) is among them. Briefly, EZH2 belongs to PRCs family and can exert functional roles in cells due to its methyltransferase activity. EZH2 affects gene expression via inducing H3K27me3. In the present review, our aim is to provide a mechanistic discussion of ncRNAs role in regulating EZH2 expression in different cancers. MiRNAs can dually induce/inhibit EZH2 in cancer cells to affect downstream targets such as Wnt, STAT3 and EMT. Furthermore, miRNAs can regulate therapy response of cancer cells via affecting EZH2 signaling. It is noteworthy that EZH2 can reduce miRNA expression by binding to promoter and exerting its methyltransferase activity. Small-interfering RNA (siRNA) and short-hairpin RNA (shRNA) are synthetic, short ncRNAs capable of reducing EZH2 expression and suppressing cancer progression. LncRNAs mainly regulate EZH2 expression via targeting miRNAs. Furthermore, lncRNAs induce EZH2 by modulating miRNA expression. Circular RNAs (CircRNAs), like lncRNAs, affect EZH2 expression via targeting miRNAs. These areas are discussed in the present review with a focus on molecular pathways leading to clinical translation.

UI MeSH Term Description Entries

Related Publications

Sepideh Mirzaei, and Mohammad Hossein Gholami, and Kiavash Hushmandi, and Farid Hashemi, and Amirhossein Zabolian, and Israel Canadas, and Ali Zarrabi, and Noushin Nabavi, and Amir Reza Aref, and Francesco Crea, and Yuzhuo Wang, and Milad Ashrafizadeh, and Alan Prem Kumar
July 2013, International journal of cancer,
Sepideh Mirzaei, and Mohammad Hossein Gholami, and Kiavash Hushmandi, and Farid Hashemi, and Amirhossein Zabolian, and Israel Canadas, and Ali Zarrabi, and Noushin Nabavi, and Amir Reza Aref, and Francesco Crea, and Yuzhuo Wang, and Milad Ashrafizadeh, and Alan Prem Kumar
August 2020, Cancer science,
Sepideh Mirzaei, and Mohammad Hossein Gholami, and Kiavash Hushmandi, and Farid Hashemi, and Amirhossein Zabolian, and Israel Canadas, and Ali Zarrabi, and Noushin Nabavi, and Amir Reza Aref, and Francesco Crea, and Yuzhuo Wang, and Milad Ashrafizadeh, and Alan Prem Kumar
January 2024, Frontiers in cell and developmental biology,
Sepideh Mirzaei, and Mohammad Hossein Gholami, and Kiavash Hushmandi, and Farid Hashemi, and Amirhossein Zabolian, and Israel Canadas, and Ali Zarrabi, and Noushin Nabavi, and Amir Reza Aref, and Francesco Crea, and Yuzhuo Wang, and Milad Ashrafizadeh, and Alan Prem Kumar
January 2018, Current gene therapy,
Sepideh Mirzaei, and Mohammad Hossein Gholami, and Kiavash Hushmandi, and Farid Hashemi, and Amirhossein Zabolian, and Israel Canadas, and Ali Zarrabi, and Noushin Nabavi, and Amir Reza Aref, and Francesco Crea, and Yuzhuo Wang, and Milad Ashrafizadeh, and Alan Prem Kumar
January 2018, Frontiers in genetics,
Sepideh Mirzaei, and Mohammad Hossein Gholami, and Kiavash Hushmandi, and Farid Hashemi, and Amirhossein Zabolian, and Israel Canadas, and Ali Zarrabi, and Noushin Nabavi, and Amir Reza Aref, and Francesco Crea, and Yuzhuo Wang, and Milad Ashrafizadeh, and Alan Prem Kumar
December 2012, Science China. Life sciences,
Sepideh Mirzaei, and Mohammad Hossein Gholami, and Kiavash Hushmandi, and Farid Hashemi, and Amirhossein Zabolian, and Israel Canadas, and Ali Zarrabi, and Noushin Nabavi, and Amir Reza Aref, and Francesco Crea, and Yuzhuo Wang, and Milad Ashrafizadeh, and Alan Prem Kumar
June 2019, Non-coding RNA research,
Sepideh Mirzaei, and Mohammad Hossein Gholami, and Kiavash Hushmandi, and Farid Hashemi, and Amirhossein Zabolian, and Israel Canadas, and Ali Zarrabi, and Noushin Nabavi, and Amir Reza Aref, and Francesco Crea, and Yuzhuo Wang, and Milad Ashrafizadeh, and Alan Prem Kumar
March 2023, Cancers,
Sepideh Mirzaei, and Mohammad Hossein Gholami, and Kiavash Hushmandi, and Farid Hashemi, and Amirhossein Zabolian, and Israel Canadas, and Ali Zarrabi, and Noushin Nabavi, and Amir Reza Aref, and Francesco Crea, and Yuzhuo Wang, and Milad Ashrafizadeh, and Alan Prem Kumar
February 2017, Biochemical Society transactions,
Sepideh Mirzaei, and Mohammad Hossein Gholami, and Kiavash Hushmandi, and Farid Hashemi, and Amirhossein Zabolian, and Israel Canadas, and Ali Zarrabi, and Noushin Nabavi, and Amir Reza Aref, and Francesco Crea, and Yuzhuo Wang, and Milad Ashrafizadeh, and Alan Prem Kumar
October 2022, Seminars in cancer biology,
Copied contents to your clipboard!